Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 10/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9811069 | 0.78 | PPIA (0.43) | PPIATNKS2SMARCA2SMARCA4PBRM1 | |
| SCHEMBL28865931 | 0.76 | PPIA (0.46) | PPIATNKS2CHRNB2CHRNA4CA1 | |
| SCHEMBL27838869 | 0.76 | PPIA (0.42) | PPIATNKS2SMARCA2SMARCA4PBRM1 | |
| SCHEMBL18243596 | 0.76 | HDAC3 (0.37) | PPIACA1CA2CA7CA9 | |
| SCHEMBL18242146 | 0.76 | HTR7 (0.41) | PPIATNKS2SMARCA2SMARCA4PBRM1 | |
| SCHEMBL8654595 | 0.76 | CHRNB2 (0.45) | PPIACHRNB2CHRNA4 | |
| SCHEMBL18243162 | 0.76 | TNKS2 (0.39) | TNKS2PBRM1 | |
| SCHEMBL18243404 | 0.76 | PPIA (0.33) | PPIACA1CA2 | |
| SCHEMBL18242828 | 0.76 | PNMT (0.42) | PPIACHRNB2CHRNA4 | |
| SCHEMBL58473 | 0.75 | GPR3 (0.46) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | CBR1, HAO2, CBR3 | PPIA 2860/4885TNKS2 2517/4885SMARCA2 3476/4885 |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | CBR1, HAO2, CBR3 | PPIA 2860/4885TNKS2 2517/4885SMARCA2 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.